420 abstracts found.



Results filter

A potent synergy between FOXG1 overexpression and Wnt signaling drives cell cycle re-entry in quiescent glioblastoma stem cells

Year:

Session type:

Faye Robertson1,Eoghan O'Duibhir1,Harry Bulstrode2,Steve Pollard1
1University of Edinburgh, Edinburgh, UK,2University of Cambridge, Cambridge, UK

Resveratrol’s effects on a BRAF mutant mouse model of colorectal carcinogenesis

Year:

Session type:

Grandezza Aburido1,Hong Cai1,Raj Singh1,Don Jones1,Rob Britton1,Karen Brown1
1University of Leicester

Top Ten Research Priorities in Cancer Early Detection: a priority setting partnership between patients and healthcare professionals

Year:

Session type:

Ellena Badrick1,Andrew Renehan1,Gen Buckley2,Lindsey Brown2,Katharine Cresswell,3,Phil Crosbie1,Clare Dickinson4,Patricia Elis5,Peter Hall6,James Leighton7,David Makin2,Lee Malcomson4,Richard Martin8,Rebecca Morris1,Helena O’Flynn9,Emma Thorpe4,Emma Crosbie1
1University of Manchester,2Public Contributor,3Manchester Foundation Trust,4Christie Hospital,5James Lind Alliance,6University of Edinburgh,7Greater Manchester Cancer,8University of Bristol,9NHS

Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets.

Year:

Session type:

Ashley Horne1,Maria McMenemy2,Holly Ennis3,Lauren Murdoch3,Grace Ding1,Olga Oikonomidou1,Caroline Michie1,Larry Haywood1,David Cameron1,Christina Lilley1,Peter Hall4,Alison Stillie1,Aisling Hennessy1,Frances Yuille1
1Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,2Lothian Analytical Services, NHS Lothian, Edinburgh, UK,3Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK,4Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK

Genetically raised serum bilirubin levels and respiratory cancer: a cohort study using UK Biobank

Year:

Session type:

Laura Horsfall1,Stephen Burgess2,Ian Hall3,Irwin Nazareth1
1University College London, London, UK,2MRC Biostatistics Unit, Cambridge, UK,3University of Nottingham, Nottingham, UK

NCRI Consumer Forum: Patients as Partners in Cancer Research 

Year:

Session type:

Richard Stephens1,Richard Stephens2,Mat Baker2,Emma Kinloch3,Liane Hazell1
1NCRI,2NCRI Consumer Forum,3NCRI Consumer Lead

Cachexia-related biomarkers predict shortened survival and treatment-related adverse outcomes in a population receiving palliative chemotherapy for lung cancer

Year:

Session type:

Joanna Bowden1,Linda Williams2,Amanda Swan3,Richard Skipworth4,Marie Fallon2
1NHS Fife, Kirkcaldy, UK, University of Edinburgh, Edinburgh, UK, University of St Andrews, St Andrews, UK,2University of Edinburgh, Edinburgh, UK,3NHS Fife, Kirkcaldy, UK ,4NHS Lothian, University of Edinburgh, Edinburgh, UK

ADSCaN: A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer (NSCLC)

Year:

Session type:

Claire Lawless1,Kathleen Boyd2,Corinne Faivre-Finn3,John Fenwick4,Tom Haswell5,David Landau6,Jason Lester7,Joe Maguire8,Elaine McCartney1,Jim Paul1,Matthew Hatton9

1CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK,2Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK,3The Christie NHS Foundation Trust, Manchester, UK,4Gray Institute of Radiation Oncology & Biology, University of Oxford, Oxford, UK,5West of Scotland Cancer Research Consumer Panel, Glasgow, UK,6Guys & St Thomas NHS Trust, London, UK,7Velindre Cancer Centre, Cardiff, UK,8Clatterbridge Cancer Centre, Liverpool, UK,9Weston Park Hospital, Sheffield, UK

Palliative radiotherapy to the oesophagus: Less is just as good.

Year:

Session type:

Shefali Parikh1,Oliver Coen1,Rebecca Goody1,Ganesh Radhakrishna2,Paul Hatfield1,Mohan Hingorani1
1Leeds Cancer Centre,2The Christie, Manchester

Predictive risk factors of venousthromboembolism (VTE) associated withperipherally inserted central catheters(PICC) in ambulant solid cancer patients:retrospective single Centre cohort study

Year:

Session type:

Osamah al-asadi1
1nhs

Defining the role of AP-1 in molecular adaptation to hypoxia in colorectal cancer

Year:

Session type:

Eric VANCAUWENBERGHE1,Hannah Bolland2,Christopher Carroll2,Leonardo Da Motta2,Anna Grabowska3,Francesca Buffa4,Adrian Harris5,Alan McIntyre2
1Hypoxia and Tumour Microenvironment Group, Cancer Biology, Division of Cancer and Stem Cells, University of Nottingham,2Hypoxia and Tumour Microenvironment Group, Cancer Biology, Division of Cancer and Stem Cells, University of Nottingham,3Cancer Biology, Division of Cancer and Stem Cells, University of Nottingham, Medical School, Queen's Medical Centre, Nottingham, UK,4Computational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford, UK,5Molecular Oncology Laboratories, Department of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Carbonic Anhydrase 9 Confers Resistance to Ferroptosis/Apoptosis in Malignant Mesothelioma Under Hypoxia

Year:

Session type:

Zan Li1,Li Jiang1,Shinya Toyokuni1
1Nagoya University Graduate School of Medicine

Factors associated with Emergency Admissions for Cancer Patients in Last year of life in a UK region

Year:

Session type:

Victoria Cairnduff1,Laura Dwyer1,Colin Fox1,Gregory Fallica2,Kelly Shiell-Davis3,Anna Gavin1
1Northern Ireland Cancer Registry, Belfast, UK,2Macmillan Cancer Support,3Macmillan Cancer Support, London, UK

RAMPART Renal Adjuvant MultiPle Arm Randomised Trial

Year:

Session type:

James Larkin1,Angela Meade2,Tom Powles3,Grant Stewart4,Bhavna Oza2,Laurence Albiges5,Axel Bex6,Hanna Bryant2,Toni Choueiri7,Ian Davis8,Tim Eisen9,Alison Fielding10,Elena Frangou2,Patrick Hanlon10,David Harrison11,Rick Kaplan2,Salena Mulhere10,Paul Nathan12,Brian Rini13,Alastair Ritchie2,Clare Shakeshaft2,Ben Smith2,Martin Stockler14,Max Parmar15
1Royal Marsden Hospital,2MRC CTU at UCL,3St Bartholomew’s Hospital,4University of Cambridge,5Institut Gustave Roussy,6Royal Free Hospital,7Dana-Farber Cancer Institute,8Monash University Eastern Health Clinical School and ANZUP Cancer Trials Group,9AstraZeneca and University of Cambridge,10Patient representative,11University of St Andrews,12Mount Vernon Cancer Centre,13Cleveland Clinic,14University of Sydney,15MCR CTU at UCL

Cell culture under perfusion conditions reduces cellular metabolic stress and mimics the in vivo physiological environment in pancreatic cancer

Year:

Session type:

Daniel Hughes1,Frances Willenbrock2,Zahir Soonawalla3,Srikanth Reddy3,Michael Silva3,Somnath Mukherjee3,Eric O'Neill2
1University of Oxford, Oxford, UK,2Department of Oncology, University of Oxford, Oxford, UK,3Oxford University Hospitals, Oxford, UK

Participant views of taking part in a tailored cancer awareness intervention: Preliminary participant interview findings from the Awareness and Beliefs About Cancer Trial (ABACus3)

Year:

Session type:

Harriet Quinn-Scoggins1,Yvonne Moriarty2,Fiona Wood1,Julia Townson2,Kate Brain1
1Division of Population Medicine, School of Medicine, Cardiff University,2Centre for Trials Research, Cardiff University

Infrared imaging to predict oral cancer development in oral epithelial dysplasia

Year:

Session type:

Barnaby Ellis1,Conor Whitley1,James Ingham1,Steve Barrett1,Peter Gardner2,Richard Shaw1,Peter Weightman1,Janet Risk1
1University of Liverpool,2University of Manchester

Making 3D possible: large scale organoid expansion using bioprocess design

Year:

Session type:

Victoria Marsh Durban1,Mairian Thomas1,Kim Luetchford1,Trevor Dale1,Marianne Ellis1
1Cellesce Ltd

Curcumin as an agent for cancer prevention in colorectal cancer

Year:

Session type:

Sam Khan1,Ankur Karmokar1,Zahirah Sidat2,Nalini Foreman1,David Moore3,Anne Thomas1,Karen Brown1
1Leicester Cancer Research Centre, Robert Kilpatrick Clinical Sciences Building, University of Leicester, Leicester,2Hope Clinical Trials Facility, Leicester Royal Infirmary, Leicester,3University College London Hospitals NHS Foundation Trust, London

A biobank analysis of outcomes in patients with malignancy of undefined primary origin

Year:

Session type:

Mark Stares1,Rebekah Patton1,Gillian Knowles1,Rachel Haigh1,Colin Barrie1,Lucy Dobbs2,Barry Laird2,Sally Clive1
1NHS Lothian,2Edinburgh University

Development of a medium-throughput colony formation screen for identification of novel radiosensitising drugs for glioblastoma

Year:

Session type:

Natividad Gomez-Roman1,Mark R Jackson1,Sandeep Chahal1,Anthony J Chalmers1
1University of Glasgow

Delineating how PIK3CA mutation and PTEN deletion contribute to prostate cancer

Year:

Session type:

Manisha Dass1,Helen Pearson1,Matthew Smalley1,Richard Clarkson1,Wayne Phillips2,Jason Li2
1European Cancer Stem Cell Research Insititute, Cardiff University,2Peter MacCallum Cancer Centre, Melbourne

Effect of lipids on IGF axis and subsequent breast cancer risk: observational and causal estimates from independent sources

Year:

Session type:

Vanessa Tan1,Caroline Bull1,Nicholas Timpson1
1University of Bristol

Estimating the gap in the provision of specialist cancer nurses in England

Year:

Session type:

Rachel White1,Jacqueline Goodchild1
1Macmillan Cancer Support

Friendship in the stable phase of cancer

Year:

Session type:

Hilde Buiting1,Michelle van Eijk2,Daniel de Vries3
1Netherlands Cancer Institute,2University of Amsterdam / Netherlands Cancer Institute,3university of Amsterdam

Microgel Matrices for Human Cancer Organoid Production

Year:

Session type:

Jessica Pinheiro de Lucena-Thomas1,Kim Luetchford2,Marianne Ellis2,Paul De Bank1
1University of Bath,2Cellesce Ltd

Hormone-related diseases and prostate cancer: an English national record linkage study

Year:

Session type:

Eleanor Watts1,Timothy Key1,Ruth Travis1,Aurora Perez-Cornago1,Raphael Goldacre1,Naomi Allen1
1University of Oxford, Oxford, UK

Understanding international variation in access to PET-CT for oncology diagnostics: An International Cancer Benchmarking Partnership (ICBP) study.

Year:

Session type:

Charlotte Lynch1,Irene Reguilon2,Deanna Langer3,Damon Lane4,Wai-Lup Wong5,Fergus McKiddie6,Andrew Ross7,Lorraine Shack8,Thida Win5,Christopher Marshall9,Mona-Elizabeth Revheim10,Bolette Danckert11,Sabina Dizdarevic5,Canice McGivern12,Anne Hazlett12,Cheryl Louzado13,Mark MacMillan8,Sam Harrison1
1Cancer Research UK, London, UK,2eConsult, London, UK,3Cancer Care Ontario, London, UK,4Pacific Radiology, New Zealand,5NHS England, London, UK,6NHS Grampian, Aberdeen, UK,7Canadian Association of Nuclear Medicine, Ottawa, Canada,8Alberta Health Services, Edmonton, Canada,9Wales Research and Diagnostic PETIC, Cardiff, UK,10Oslo University Hospital, Oslo, Norway,11Aarhus University, Aarhus, Denmark,12Belfast Health and Social Care Trust, Belfast, UK,13Canadian Partnership Against Cancer, Toronto, Canada

Delivery of radiotherapy clinical trials: Recommendations for best practice across Clinical Trial Units (CTU) and the National Radiotherapy Trials Quality Assurance Group (RTTQA)

Year:

Session type:

Lisette Nixon1,Elizabeth Miles2,Natalie Abbott3,Sue Bell4,Clare Cruickshank5,Patty Diez6,Alexandra Smith4,Yat Tsang6,Emma Hall5,on behalf of CTRad7
1Cardiff University, Cardiff, UK,2Coordinator National Radiotherapy Trials QA (RTTQA) Group, London, UK, Mount Vernon Cancer Centre, Northwood, UK,3Velindre Cancer Centre, Cardiff, UK,4University of Leeds, Leeds, UK,5The Institute of Cancer Research, London, UK,6Mount Vernon Cancer Centre, Northwood, UK,7National Cancer Research Institute, London, UK

Antiproliferation and anti-invasion of 1’-Acetoxychavicol acetate on hormonal-resistant breast cancer cells

Year:

Session type:

Nalinee Pradubyat1,Wannarasmi Ketchart2,Carlo Palmieri3,Athina Giannoudis4
1University of Liverpool,2Faculty of Medicine, Chulalongkorn University,3Institute of Translational Medicine, University of Liverpool, Clatterbridge Cancer Centre, UK,4Institute of Translational Medicine, University of Liverpool

An Analysis of Prognostic Biomarkers of the Systemic Inflammatory Response in Cancers of Unknown Primary

Year:

Session type:

Rebekah Patton1,Rebekah Patton1,Gillian Knowles1,Rachel Haigh1,Lucy Dobbs2,Barry Laird1,Colin Barrie1,Sally Clive1
1NHS Lothian, Edinburgh, UK,2University of Edinburgh, Edinburgh, UK

Next generation Cytogenetics: Comprehensive Structural Analysis of Cancer Genomes by Optical Genome Mapping

Year:

Session type:

Ernest Lam1,Andy Peng2,Alex Hastie1,Yannick Delpu1
1Bionano Genomics,2Bionano Genomcis

Proteomic Profiling on apoptotic effect of keto-boswellic acid

Year:

Session type:

Fahad AL Zadjali1,Asma Bani Oraba1
1Sultan Qaboos University

Cancer Quality of Life Metric Project – Lessons learned from an implementation pilot

Year:

Session type:

Alice Simon1,Sarah Gelcich2,Adam Glaser3,Andria Hanbury4,Luke Hounsome5,Jane Maher6,Erik Mayer7,Alison Richardson8,Simon Rogers9,Lesley Smith10,Galina Velikova2,and the NHS England Cancer Quality of Life Working and Steering Groups10
1NHS England, London UK,2University of Leeds, Leeds, UK,3University of Leeds,4York Health Economics Consortium, York, UK,5Public Health England,6Macmillan Cancer Support, London UK, Mount Vernon Cancer Centre, Northwood, UK,7Imperial College Healthcare NHS Trust, London, UK, The Royal Marsden NHS Foundation Trust, London, UK,8University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK,9Aintree University Hospital NHS Foundation Trust, Liverpool, UK,10NHS England, London, UK

Making Big Data available: Informatics Infrastructure supporting the MRC/CRUK funded Stratification in COloRecTal Cancer (S-CORT) programme

Year:

Session type:

Andrew Blake1,Enric Domingo1,Michael Youdell1,Susan Richman2,Peter Stewart3,Celina Whalley4,Clare Hardy5,Katerina Chatazipli5,on behalf of S-CORT Consortium6,Tim Maughan1
1University of Oxford,2University of Leeds,3Queens University Belfast,4University of Birmingham,5Wellcome Trust Sanger Institute,6S-CORT Consortium

Mutation analysis of Beta2-Microglobulin identifies a subset of deficient mismatch repair (dMMR) colorectal cancers which are protected from disease recurrence.

Year:

Session type:

Susan Richman1,Paul Barrow2,Andrew Wallace3,Kelly Handley4,Gordon Hutchins5,David Kerr6,Laura Magill4,Gareth Evans3,Richard Gray6,Phil Quirke5,James Hill2
1Leeds Teaching Hospitals NHS Trust,2Manchester Royal Infirmary,3Central Manchester University Hospitals NHS Trust,4University of Birmingham,5University of Leeds,6University of Oxford

Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology?

Year:

Session type:

Victoria Aubrey1,Clare Shaw2
1The Royal Marsden NHS Foundation Trust,2Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London and Sutton

Phenotyping neutrophil subpopulations in advanced lung cancer

Year:

Session type:

Robert Grecian1,Patricia Dos Santos Coelho1,Emily Watts1,Kev Dhaliwal1,Adam Byron1,Margaret Frame1,Moira Whyte1,Sarah Walmsley1
1Edinburgh University

Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model

Year:

Session type:

Pavlina Spiliopoulou1,Sarah Spear2,Patricia Roxburgh3,Susanne Dowson4,Susan Mason4,Karen Blyth4,Matthew Fuchter2,Bob Brown2,Iain A McNeish2
1Beatson West of Scotland Cancer Centre, Glasgow, UK,2Imperial College London, London, UK,3Beatson West of Scotland Cancer Centre,4University of Glasgow, Glasgow, UK

The p53/p21 axis suppresses 5FU-induced, ATM/ATR-STAT3-mediated activation of PD-L1

Year:

Session type:

Tamas Sessler1,Fiammetta Falcone2,Peter Gallagher2,Daniel Longley2,Simon McDade2
1Centre for Cancer Research & Cell Biology Queen's University Belfast, Belfast, UK, Forensic Geoscience Group Queen's University Belfast, Belfast, UK,2Queen's University Belfast, Belfast, UK

Costs to patients and health service associated with immune checkpoint inhibitor-mediated colitis – a single site experience.

Year:

Session type:

Binu Chandrasekharapillai Janardanan Nair1,Dana Shor1,Tim Raine1,Pippa Corrie1,Sarah J Welsh1
1Cambridge University Hospitals NHS Foundation Trust

The impact of type 2 diabetes on survival in patients with cancer independent of its effect on survival in individuals without cancer: a matched cohort analysis

Year:

Session type:

Andrew Renehan1,Nasra Alam1,Alison Weight1,Martin Rutter1,Matthew Sperrin1,Darren Ashcroft1,Andrew Renehan1
1University of Manchester, Manchester, UK

Cancer Work Support Service (CWSS): An innovative Vocational Rehabilitation service supporting cancer survivors return to work

Year:

Session type:

Julie Denning1
1Working To Wellbeing

Co-design of a remote monitoring application for the first month following colorectal cancer surgery

Year:

Session type:

Morven Miller1,John Connaghan1,Lisa McCann1,Hester Van-Wyk2,Campbell Roxburgh2,Roma Maguire1
1University of Strathclyde,2University of Glasgow

A multiplex proteomics analysis reveals a novel plasma biomarker signature that predicts for outcomes in gastro-oesophageal cancer

Year:

Session type:

Eilidh McCulloch1,Alan Bilsland1,Liz-Anne Lewsley2,Antonia MacMillan2,Martin MacLeod2,Jennifer Walker1,Jamie Stobo2,James Paul2,W. Nicol Keith1,Patricia Roxburgh1,Fiona Thomson1,T.R. Jeffry Evans1
1Glasgow ECMC, Institute of Cancer Science, University of Glasgow,2CRUK Clinical Trials Unit, Institute of Cancer Science, University of Glasgow

Best Supportive Care in cancer: working models require both resource and accountability for delivery if patients are to benefit.

Year:

Session type:

Joanna Bowden1,Mhairi Gilmour2,Steinunn Boyce2,Jane Wilson2
1NHS Fife, Kirkcaldy, UK, University of Edinburgh, Edinburgh, UK, University of St Andrews, St Andrews, UK,2NHS Fife

EXPERIENCE WITH CDK4/6 INHIBITORS: A SINGLE INSTITUTION STUDY

Year:

Session type:

Sarah Saeed Qureshi1,Muhammad Farooq Latif1,Syed Hammad Tirmazy1
1Dubai Hospital

Impact of body fatness and metabolic traits on colorectal cancer

Year:

Session type:

Emma Vincent1,Caroline Bull1,Joshua Bell1,Neil Murphy1,Nicholas Timpson1,Marc Gunter2
1University of Bristol,2International Agency of Research on Cancer

Incidence and management of 3 years of immune mediated toxicities in metastatic non-small cell lung carcinoma (NSCLC) patients treated with anti PD-1/PD-L1 immunotherapy

Year:

Session type:

Grace Tze-en Ding1,Colin Barrie1,Alan Simms2,Melanie Mackean3
1Edinburgh Cancer Centre,2Department of Radiology, NHS Lothian,3Edinburgh

Does testosterone mediate the relationship between vitamin D and prostate cancer?

Year:

Session type:

Luke Robles1,Sean Harrison1,Vanessa Tan1,Rhona Beynon1,Alexandra McAleenan1,Karen Dawe1,Tom Gaunt1,Julian Higgins1,Richard Martin1,Sarah Lewis1
1University of Bristol